Sign In
Buy SGMT
$6.86
+0.0700 (+1.03%)
At Close: Jun 03, 2026
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
06:30am, Tuesday, 12'th Nov 2024
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc.
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
03:10pm, Friday, 18'th Oct 2024
Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's u
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis - - Results support advancement of denifanstat
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
04:01pm, Wednesday, 02'nd Oct 2024
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
07:00am, Tuesday, 01'st Oct 2024
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024 SAN MATEO, Calif
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
07:30am, Thursday, 12'th Sep 2024
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor
3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts
03:27pm, Monday, 12'th Aug 2024
Penny stocks are a fascinating category of investment opportunities.
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
08:00am, Thursday, 01'st Aug 2024
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors
Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
12:24pm, Wednesday, 31'st Jul 2024
Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive res
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance f
Leerink Partnrs Weighs in on Sagimet Biosciences Inc.’s Q2 2024 Earnings (NASDAQ:SGMT)
01:06am, Monday, 20'th May 2024
Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Analysts at Leerink Partnrs increased their Q2 2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a researc
Sagimet Biosciences Inc. to Post Q2 2024 Earnings of ($0.40) Per Share, HC Wainwright Forecasts (NASDAQ:SGMT)
01:06am, Monday, 20'th May 2024
Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Analysts at HC Wainwright raised their Q2 2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a report relea
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet's topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH
